Lion Bio reports first patient dosed in second cohort of LN-144 study
Lion Biotechnologies announced that the first patient was dosed in the second cohort of its ongoing Phase 2 trial of LN-144 for the treatment of patients with metastatic melanoma. This cohort utilizes the company's generation 2 manufacturing process which includes cryopreservation of the outbound products. "We are pleased to be able to offer a shorter manufacturing process for TIL to the melanoma patients enrolling in Cohort 2 of LN-144 trial. This process reduces the time from excision to infusion from approximately six weeks to just over three weeks and includes cryopreservation for the outbound product," said CEO Maria Fardis. Lion Biotechnologies will be releasing interim data from the first cohort of this study at the upcoming 2017 American Society of Clinical Oncology Annual Meeting from June 2-6.